Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach. - Wikidata - wikimedia - TriplyDB

Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.

Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.

http://www.wikidata.org/entity/Q33372266

about

Economic burden of venous thromboembolism in hospitalized patients.The importance of appropriate prophylaxis for the prevention of venous thromboembolism in at-risk medical patients.

P2860

Q34994523-CF79B5B1-4E90-4611-9B2C-AC678D96637B Q37789425-01F344C6-B98D-4CC8-8932-43EFB9E52F1F

P2860

Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.

http://www.wikidata.org/entity/Q33372266

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Choosing the appropriate antit ...... of VTE: a case-based approach.

@ast

Choosing the appropriate antit ...... of VTE: a case-based approach.

@en

type

label

Choosing the appropriate antit ...... of VTE: a case-based approach.

@ast

Choosing the appropriate antit ...... of VTE: a case-based approach.

@en

prefLabel

Choosing the appropriate antit ...... of VTE: a case-based approach.

@ast

Choosing the appropriate antit ...... of VTE: a case-based approach.

@en

P1433

Q33372266-62D0BBDB-89A4-4415-8BF5-0D8AC461705C

P1476

Q33372266-C999CE29-DB3F-4B03-993E-EFF314C31430

P2093

Q33372266-0120EFF3-C05F-4616-82BF-3A0D9BC6D781

Q33372266-3AE826A5-0CBF-4C69-BD0E-CD58AF4DE95F

Q33372266-5367FC46-44DE-433A-B975-DA7501BC1150

Q33372266-57D764AF-87AF-4826-9181-7EFB18C270FB

Q33372266-EF9C5AF2-50AD-4A0E-ABA7-229394608427

P2860

Q33372266-060309A3-9E0A-4E3F-B4B8-AD2B32159A30

Q33372266-0617C1B2-1D88-474C-ADF2-72E627C34407

Q33372266-0DECB03E-43BE-4F9A-86B6-0C5AE6BD0270

Q33372266-10E630D5-B54A-42A8-BA73-6AF5A19B32E6

Q33372266-1D7C080B-48AB-4B40-9D0B-46D4054303D9

Q33372266-2242E7DD-1E06-4B19-95FE-2DDE4FE254E3

Q33372266-25A1F326-8FF4-45A1-A347-757A8795BBF3

Q33372266-270B2574-A74B-4F42-9AE7-A23A6CC92F5A

Q33372266-2AC7169C-59BE-48C2-9C78-C04BA8E8890A

Q33372266-3572375E-6048-4E59-AA7C-DE1C36F9D0C3

P304

Q33372266-8BA1D0D5-7E89-440B-AE10-31C0389AE371

P31

Q33372266-6888F756-7DC2-4325-A854-82DD4375167B

P356

Q33372266-23DA98CB-D82C-4A0F-B45E-A5DAC973FA77

P407

Q33372266-B60B9D2A-624E-4F88-BD69-12FB33B96E49

P433

Q33372266-22BAA3B2-1A09-4007-9DBC-189AA5070FD5

P478

Q33372266-72AF5948-ED6F-4533-9C19-65FAF15B89D6

P577

Q33372266-AD788793-7531-4F34-9F51-60ACD95769B2

P698

Q33372266-47E9248F-B1FB-4B88-A632-834A666D19FA

P356

P1433

Annals of Pharmacotherapy

P1476

Choosing the appropriate antit ...... of VTE: a case-based approach.

@en

P2093

Ann K Wittkowsky

http://www.w3.org/2001/XMLSchema#string

David W Hawkins

http://www.w3.org/2001/XMLSchema#string

Edith A Nutescu

http://www.w3.org/2001/XMLSchema#string

Paul P Dobesh

http://www.w3.org/2001/XMLSchema#string

William E Dager

http://www.w3.org/2001/XMLSchema#string

P2860

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.

Treatment of heparin-induced thrombocytopenia.

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.

Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy.

Heparin-induced thrombocytopenia: pathogenesis and management.

P304

1558-1571

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1G577

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16912250

http://www.w3.org/2001/XMLSchema#string